B7-33
A compound aimed at reducing scar-tissue buildup (fibrosis). A single-chain peptide derivative of relaxin, designed to retain anti-fibrotic activity without the cardiovascular side profile of full relaxin. Pre-clinical / early human research.
B7-33: A compound aimed at reducing scar-tissue buildup (fibrosis). A single-chain peptide derivative of relaxin, designed to retain anti-fibrotic activity without the cardiovascular side profile of full relaxin. Pre-clinical / early human research. B7-33 is a single-chain fragment of relaxin designed to keep the anti-fibrotic effect (good for hearts, kidneys, lungs) without dropping blood pressure (the side effect of full relaxin).
B7-33 is a single-chain fragment of relaxin designed to keep the anti-fibrotic effect (good for hearts, kidneys, lungs) without dropping blood pressure (the side effect of full relaxin). Pre-clinical only. Don't use this without medical oversight.
Who it's for
- →Researchers studying fibrotic disease pathways
- →Cardiovascular-research context only
- →Educational reference, not for community use
What to expect
- Week 1
No documented human user reports of acute effects.
- Week 4
Pre-clinical models show anti-fibrotic markers shifting around here.
- Week 8
No long term human data exists.
Looking at B7-33? Your next 3 steps
- 1Work out your exact dose
Vial size + BAC water turns into the exact units to draw for B7-33.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account saves your stack; membership adds the stack-aware AI Coach.
Create free account →
How it works (mechanism)
Single-chain peptide derivative of relaxin that retains binding to relaxin receptor RXFP1 with anti-fibrotic signaling, but lacks the cardiovascular receptor crosstalk responsible for relaxin's hypotensive effect.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Hypotension or unstable cardiovascular status
- ⚠Pregnancy / nursing
- ⚠Anyone risk-averse to pre-clinical-only data
Common mistakes
- • Treating community-vendor B7-33 as research grade clinical material
- • Running it without published human safety data
- • Stacking it with anything else
New to B7-33? Grab the starter checklist.
Drop your email and we'll send the one-page first-cycle starter checklist, plus a heads-up if B7-33 changes legal status. No account needed.
No spam. No selling your email. Just the checklist and the occasional reclassification alert.
Ask the Coach anything about B7-33 or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Get the Coach, $7.99/mo →Frequently asked
What is B7-33?+
Is B7-33 FDA approved?+
Is B7-33 legal?+
Is B7-33 banned by WADA?+
Are you still natty after taking B7-33?+
Do doctors prescribe B7-33?+
What's the typical dose of B7-33?+
What are the side effects of B7-33?+
How long until B7-33 starts working?+
What can you stack with B7-33?+
Where do people get B7-33?+
More in Healing
Synthetic peptide derived from a stomach protein. Used to speed up tendon, ligament, and gut healing.
A fragment of Thymosin Beta-4. Drives cell migration and tissue repair, used for chronic soft-tissue stuff.
A bone-building drug. A parathyroid-hormone fragment (PTH 1-34), FDA-approved as Forteo for severe osteoporosis. Anabolic for bone, the opposite of bisphosphonates.
A compound studied for calming nerve pain and inflammation without raising red blood cells. An EPO-derived peptide that targets the innate-repair receptor without the red-blood-cell side of erythropoietin, studied for neuropathic pain, sarcoidosis, and diabetic complications.